Poloxamer: A Simple And Powerful Solution For Accelerating Dissolution

By Daniel Joseph Price

Poor oral bioavailability is often framed as a solubility problem, but in many cases, the real bottleneck is how quickly a molecule dissolves once it enters the gastrointestinal tract. This white paper explores the practical distinction between solubility and dissolution rate and why that difference matters during formulation development. Using the Developability Classification System (DCS) as a guide, it explains how dissolution‑rate-limited compounds can benefit from targeted formulation strategies rather than complex solubility‑enhancing approaches. Particular attention is given to the role of amphiphilic excipients, such as poloxamers, in improving diffusion at the solid-liquid interface. By accelerating dissolution without adding manufacturing complexity, formulators can improve absorption potential while maintaining straightforward, scalable processes.

Read on to better align formulation choices with the true developability risks of poorly soluble APIs.